A method for producing tablets with an active substance including inputting a target number of tablets to produce and a target mass indicating the quantity of active substance per tablet, transmitting the target number and target mass to a controller configured to control a dosing device, a weighing device, extendable upper and lower punches, filling a quantity of the active substance from a container into an opening of a die. While filling, a pressure face of the lower punch closes the opening, and the amount of the active substance is measured by the weighing device on which the lower punch and the die are placed while filling. The method further including pressing the active substance, releasing a pressed tablet from the die, and repeating the repeating the process until the target number is reached.

A method for producing tablets with an active substance including inputting a target number of tablets to produce and a target mass indicating the quantity of active substance per tablet, transmitting the target number and target mass to a controller configured to control a dosing device, a weighing device, extendable upper and lower punches, filling a quantity of the active substance from a container into an opening of a die. While filling, a pressure face of the lower punch closes the opening, and the amount of the active substance is measured by the weighing device on which the lower punch and the die are placed while filling. The method further including pressing the active substance, releasing a pressed tablet from the die, and repeating the repeating the process until the target number is reached.

A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.

A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a disintegrant, a surfactant, a binder, and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Processes of preparing pharmaceutical compositions comprising Compound 1 are also disclosed.

A process is disclosed for the manufacture of a compressed product consisting of a multilayer tablet formed in a single compression operation.

A process is disclosed for the manufacture of a compressed product consisting of a multilayer tablet formed in a single compression operation.

A modular system for producing dosage-form bulk material in the form of dosage-form base materials or dosage forms. The system includes at least one processing unit (2) which includes a plurality of process stations, at least one container for receiving dosage-form bulk material, and at least one handling system, the at least one handling system transferring the containers between process stations. Also described is a method for producing dosage-form bulk material.

A modular system for producing dosage-form bulk material in the form of dosage-form base materials or dosage forms. The system includes at least one processing unit (2) which includes a plurality of process stations, at least one container for receiving dosage-form bulk material, and at least one handling system, the at least one handling system transferring the containers between process stations. Also described is a method for producing dosage-form bulk material.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and a mouth-soluble binder dispersed in the mouth-stable polymer matrix.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and a mouth-soluble binder dispersed in the mouth-stable polymer matrix.